Study enrollment and participants
MAY
The trial was centrally activated on 17 October 2019 and was closed to accrual on 5 April 2022 after reaching target enrollment (study completion as per protocol). The first and last patients were enrolled on trial on 26 May 2020 and 5 April 2022, respectively. A total of 50 patients were accrued to the trial; all patients were followed for ctDNA molecular response and clinical response for a minimum of 12 weeks, and the clinical trial database was locked on 20 September 2022 (Fig. 